M Ali1, P Lyden, R L Sacco, A Shuaib, K R Lees. 1. Department of Medicine & Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK. myzoonali@clinmed.gla.ac.uk
Abstract
BACKGROUND AND PURPOSE: Numerous trials of haemostatic and neuroprotective agents for intracerebral haemorrhage (ICH) have failed. We characterized the risk of complications after ICH in a trial-eligible patient population, to inform safety in future trials. METHODS: We used the Virtual International Stroke Trials Archive database to identify placebo-treated patients with spontaneous ICH, who were not comatose at admission, where randomization took place within 4 h of symptom onset, and where serious complication and outcome data were available. We described the complications encountered and assessed whether the absence of common complications influenced attainment of good functional outcome (mRS < or =4) at 90 days using logistic regression. RESULTS: Of 201 patients examined, 70.2% experienced at least one serious complication. Neurological complications occurred in 21%, infections amongst 11%, and thromboembolic complications in 2%. Extension of the haemorrhage occurred most frequently: its absence was a significant predictor of good functional outcome (P < 0.0001, adjusted OR for good functional outcome = 21.9, 95% CI: [5.5, 88.3]). Neither infection, nor cardiac, nor thromboembolic complications influenced functional outcome at 90 days. CONCLUSIONS: Three month outcome in ICH patients depends on initial stroke severity and on enlargement of the haemorrhage. Our results should inform safety in future clinical trials of putative ICH therapies.
BACKGROUND AND PURPOSE: Numerous trials of haemostatic and neuroprotective agents for intracerebral haemorrhage (ICH) have failed. We characterized the risk of complications after ICH in a trial-eligible patient population, to inform safety in future trials. METHODS: We used the Virtual International Stroke Trials Archive database to identify placebo-treated patients with spontaneous ICH, who were not comatose at admission, where randomization took place within 4 h of symptom onset, and where serious complication and outcome data were available. We described the complications encountered and assessed whether the absence of common complications influenced attainment of good functional outcome (mRS < or =4) at 90 days using logistic regression. RESULTS: Of 201 patients examined, 70.2% experienced at least one serious complication. Neurological complications occurred in 21%, infections amongst 11%, and thromboembolic complications in 2%. Extension of the haemorrhage occurred most frequently: its absence was a significant predictor of good functional outcome (P < 0.0001, adjusted OR for good functional outcome = 21.9, 95% CI: [5.5, 88.3]). Neither infection, nor cardiac, nor thromboembolic complications influenced functional outcome at 90 days. CONCLUSIONS: Three month outcome in ICHpatients depends on initial stroke severity and on enlargement of the haemorrhage. Our results should inform safety in future clinical trials of putative ICH therapies.
Authors: Santosh B Murthy; Yogesh Moradiya; Jharna Shah; Alexander E Merkler; Halinder S Mangat; Costantino Iadacola; Daniel F Hanley; Hooman Kamel; Wendy C Ziai Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210
Authors: Aaron S Lord; Carl D Langefeld; Padmini Sekar; Charles J Moomaw; Neeraj Badjatia; Anastasia Vashkevich; Jonathan Rosand; Jennifer Osborne; Daniel Woo; Mitchell S V Elkind Journal: Stroke Date: 2014-10-14 Impact factor: 7.914
Authors: Craig J Smith; Benjamin D Bray; Alex Hoffman; Andreas Meisel; Peter U Heuschmann; Charles D A Wolfe; Pippa J Tyrrell; Anthony G Rudd Journal: J Am Heart Assoc Date: 2015-01-13 Impact factor: 5.501
Authors: Amelia K Boehme; Mary E Comeau; Carl D Langefeld; Aaron Lord; Charles J Moomaw; Jennifer Osborne; Michael L James; Sharyl Martini; Fernando D Testai; Daniel Woo; Mitchell S V Elkind Journal: Neurol Neuroimmunol Neuroinflamm Date: 2017-12-22
Authors: Anna Lindner; Mario Kofler; Verena Rass; Bogdan Ianosi; Max Gaasch; Alois J Schiefecker; Ronny Beer; Sebastian Loveys; Paul Rhomberg; Bettina Pfausler; Claudius Thomé; Erich Schmutzhard; Raimund Helbok Journal: Front Neurol Date: 2019-08-06 Impact factor: 4.003